Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Account Payables: 2020-2024

Historic Change in Account Payables for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $6.3 million.

  • Monte Rosa Therapeutics' Change in Account Payables rose 473.11% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 892.86%. This contributed to the annual value of $6.3 million for FY2024, which is 8.58% up from last year.
  • Monte Rosa Therapeutics' Change in Account Payables amounted to $6.3 million in FY2024, which was up 8.58% from $5.8 million recorded in FY2023.
  • Over the past 5 years, Monte Rosa Therapeutics' Change in Account Payables peaked at $6.3 million during FY2024, and registered a low of -$744,000 during FY2022.
  • For the 3-year period, Monte Rosa Therapeutics' Change in Account Payables averaged around $3.8 million, with its median value being $5.8 million (2023).
  • Per our database at Business Quant, Monte Rosa Therapeutics' Change in Account Payables slumped by 120.55% in 2021 and then skyrocketed by 873.92% in 2023.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Change in Account Payables stood at $3.4 million in 2020, then slumped by 120.55% to -$706,000 in 2021, then dropped by 5.38% to -$744,000 in 2022, then surged by 873.92% to $5.8 million in 2023, then increased by 8.58% to $6.3 million in 2024.